Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023;18(2):141-147.
doi: 10.5114/pg.2023.129412. Epub 2023 Jul 27.

Biological markers of disease activity in inflammatory bowel diseases

Edyta Szymanska  1 , Sylwia Szymanska  1 , Maciej Dadalski  1 , Jaroslaw Kierkus  1
Affiliations
Review

Biological markers of disease activity in inflammatory bowel diseases

Edyta Szymanska et al. Prz Gastroenterol. 2023.

Abstract

Inflammatory bowel diseases (IBD) are chronic intestinal conditions of multifactorial aetiology including genetic susceptibility, immunological impairment, dysbiosis, and environmental factors. The diagnosis is based on both clinical and endoscopic features, wherein histopathological evaluation remains a gold diagnostic standard. However, fast, reliable, and non-invasive biological markers have been used for years for diagnosis as well as for disease activity monitoring. Currently, commonly used faecal calprotectin is the only biomarker approved and recommended by the European Crohn's and Colitis Organization (ECCO). Nonetheless, other biological markers discriminating between functional and organic bowel conditions have been widely studied. Therefore, the aim of this manuscript was to review new potential biomarkers of inflammation in IBD. The aim of this study was to review currently available biomarkers of intestinal inflammation and increased gut permeability in IBD.

Keywords: biomarkers; elafin; faecal calprotectin; haptoglobin; inflammatory bowel disease; zonulin.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Flynn S, Eisenstein S. Inflammatory bowel disease presentation and diagnosis. Surg Clin North Am 2019; 99: 1051-62. - PubMed
    1. Malik TA. Inflammatory bowel disease: historical perspective, epidemiology, and risk factors. Surg Clin North Am 2015; 95: 1105-22. - PubMed
    1. Zhang YZ, Li YY. Inflammatory bowel disease: pathogenesis. World J Gastroenterol 2014; 20: 91-9. - PMC - PubMed
    1. Geremia A, Biancheri P, Allan P, et al. . Innate and adaptive immunity in inflammatory bowel disease. Autoimmun Rev 2014; 13: 3-10. - PubMed
    1. Torres J, Bonovas S, Doherty G, et al. . ECCO Guidelines on therapeutics in Crohn’s disease: medical treatment. J Crohns Colitis 2020; 14: 4-22. - PubMed